Less than two months after saying that it would wind down its business of stem cell-based therapies for blood cancers, Vor Bio of the US has bounced back, rebranding as an autoimmune disease company and inking a deal potentially worth over $4bn to bag rights to Chinese firm RemeGen’s telitacicept.
Key Takeaways
- Vor is paying $125m upfront to RemeGen for rights to its BAFF/APRIL inhibitor telitacicept.
The Cambridge, MA-based biotech has entered into a license agreement with RemeGen for the dual-target fusion protein which is
Welcome to Scrip
Create an account to read this article
Already a subscriber?